125I seed implantation combined with chemotherapy in the treatment of non-small cell lung carcinoma
- Author:
Xue-Ming DU
1
Author Information
1. Department of Interventional Therapy
- Publication Type:Journal Article
- Keywords:
125I seed;
Brachytherapy;
Carcinoma;
Non-small cell lung carcinoma;
Radiology, interventional
- From:
Tumor
2007;27(5):406-408
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical efficacy of 125I seed implantation combined with chemotherapy in the treatment of non-small cell lung carcinoma (NSCLC) and its complications. Methods: Combined treatment group (n = 42) received CT-guided interstitial 125I seed implantation (PD = 8-10 Gy/h), and three days later they were given TAX + DDP intravenous chemotherapy. Control group (n = 46) only received TAX + DDP chemotherapy. The dosage was selected based on the same reference standard as the treatment group. The therapeutic efficacy was observed two months later. The life quality of patients was evaluated by using EORTC QLQ-C30 table. Results: Both the technical success rate and follow-up rate were all 100%. In combined treatment group 4 patients achieved complete response (CR, 9.5%), 14 patients had partial response (PR, 33.3%), 20 patients with stable disease (SD, 47.6%) and 4 patients with progressed disease (PD, 9.5%). The total response rate (CR + PR) was 42.9%. In control group 1 patient achieved complete response (2.2%), 8 patients had partial response (17.4%), 22 patients with stable disease (47.8%) and 15 patients with progressed disease (32.6%). The total response rate (CR + PR) was 19.6%. The total response rate of the treatment group was significantly higher than control group. Conclusion: 125I seed implantation is synergistic with chemotherapy which is beneficial in reducing tumor load in a short period and increased the short β2-MG term therapeutic efficacy for NSCLC.
